Varlilumab: A Deep Dive into CDX-1127 and its Mechanism Varlilumab (formerly known as CDX-1127) represents an innovative therapeutic agent targeting the CD27 receptor. The drug's mode of action involves association to CD27, a cell surface molecule critical for immune response and anti-tumor immunity. By stimulating the CD27 route, this… Read More

Olaratumab, previously identified as LY3012207 and subsequently recognized as IMC-3G3, represents a unique novel monoclonal antibody therapeutic agent targeting the tumor-associated glycoprotein podoplanin PDPN gp38. This The It antibody exhibits demonstrates shows a particular distinct mechanism of action, primarily mostly largely mediating ant… Read More